Insulin-like growth factor (IGF) family and prostate cancer

[en] There is abundant in vitro, animal and epidemiologic evidence to suggest that the Insulin-Like Growth Factor (IGF) family is a multicomponent network of molecules which is involved in the regulation of both physiological and pathological growth processes in prostate. The IGF family plays a key role in cellular metabolism, differentiation, proliferation, transformation and apoptosis, during normal development and malignant growth. This family also seem essential in prostate cancer bone metastases, angiogenesis and androgen-independent progression. Therapeutic alternatives in men with progressive prostate cancer after androgen ablation are very limited. More effective therapies are needed for these patients. Pharmacologic interventions targeting the IGF family are being devised. Such strategies include reduction of IGF-I levels (growth hormone-releasing hormone antagonists, somatostatin analogs), reduction of functional IGF-I receptor levels (antisense oligonucleotides, small interfering RNA), inhibition of IGF-IR and its signalling (monoclonal antibodies, small-molecule tyrosine kinase inhibitors) and Insulin-Like Growth Factor Binding Proteins. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

Disciplines :

Oncology
Hematology

Author, co-author :

Gennigens, Christine ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale

Menetrier-Caux, C.

Droz, J. P.

Language :

English

Title :

Insulin-like growth factor (IGF) family and prostate cancer

Publication date :

May 2006

Journal title :

Critical Reviews in Oncology/Hematology

ISSN :

1040-8428

eISSN :

1879-0461

Publisher :

Elsevier Science Inc, New York, United States - New York

Volume :

Issue :

Pages :

124-145

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 30 November 2013

Statistics

Number of views

58 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

127

Scopus citations^®
without self-citations

127

OpenCitations

109

Bibliography

Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36 10 (2000) 1224-1228
Pollak M., Beamer W., and Zhang J.C. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17 4 (1998-89) 383-390
Harman S.M., Metter E.J., Blackman M.R., Landis P.K., and Carter H.B. Baltimore Longitudinal Study on Aging. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85 11 (2000) 4258-4265
Chokkalingam A.P., Pollak M., Fillmore C.M., et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 10 5 (2001) 421-427
Sandhu M.S., Dunger D.B., and Giovannucci E.L. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 94 13 (2002) 972-980
Ma J., Pollak M.N., Giovannucci E., et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91 7 (1999) 620-625
Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., and Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91 2 (1999) 151-156
Toniolo P., Bruning P.F., Akhmedkhanov A., et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88 5 (2000) 828-832
Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 9113 (1998) 1393-1396
Mohan S., and Baylink D.J. IGF-binding proteins are multifunctional and act via IGF-dependent and-independent mechanisms. J Endocrinol 175 1 (2002) 19-31
Khandwala H.M., McCutcheon I.E., Flyvbjerg A., and Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21 June (3) (2000) 215-244
Kahn C.R. The molecular mechanism of insulin action. Annu Rev Med 36 (1985) 429-451
Thissen J.P., Ketelslegers J.M., and Underwood L.E. Nutritional regulation of the insulin-like growth factors. Endocr Rev 15 1 (1994) 80-101
Moschos S.J., and Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63 4 (2002) 317-332
Yu H., and Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92 September (18) (2000) 1472-1489
Rosenthal S.M., Brown E.J., Brunetti A., and Goldfine I.D. Fibroblast growth factor inhibits insulin-like growth factor-II (IGF-II) gene expression and increases IGF-I receptor abundance in BC3H-1 muscle cells. Mol Endocrinol 5 5 (1991) 678-684
Rubini M., Werner H., Gandini E., Roberts Jr. C.T., LeRoith D., and Baserga R. Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-1 (IGF-1) receptor gene. Exp Cell Res 211 2 (1994) 374-379
Zapf J. Physiological role of the insulin-like growth factor binding proteins. Eur J Endocrinol 132 June (6) (1995) 645-654
Baxter R.C. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 42 4-5 (1994) 140-144
Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16 1 (1995) 3-34
Furlanetto R.W., Harwell S.E., and Frick K.K. Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 8 April (4) (1994) 510-517
Parrizas M., and LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138 March (3) (1997) 1355-1358
Akagi Y., Liu W., Zebrowski B., Xie K., and Ellis L.M. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58 17 (1998) 4008-4014
Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., and Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277 41 (2002) 38205-38211
Playford M.P., Bicknell D., Bodmer W.F., and Macaulay V.M. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 97 22 (2000) 12103-12108
Liu J.P., Baker J., Perkins A.S., Robertson E.J., and Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75 1 (1993) 59-72
Abuzzahab M.J., Schneider A., Goddard A., et al., Intrauterine Growth Retardation (IUGR) Study Group. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 349 23 (2003) 2211-2222
Powell-Braxton L., Hollingshead P., Warburton C., et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 7 12B (1993) 2609-2617
Sell C., Rubini M., Rubin R., Liu J.P., Efstratiadis A., and Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90 23 (1993) 11217-11221
Sell C., Dumenil G., Deveaud C., et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14 6 (1994) 3604-3612
Yee D. The insulin-like growth factor system as a treatment target in breast cancer. Semin Oncol 29 3 Suppl. 11 (2002) 86-95
Van Wyk J.J., and Smith E.P. Insulin-like growth factors and skeletal growth: possibilities for therapeutic interventions. J Clin Endocrinol Metab 84 12 (1999) 4349-4354
O'Gorman D.B., Weiss J., Hettiaratchi A., Firth S.M., and Scott C.D. Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology 143 11 (2002) 4287-4294
Li J., and Sahagian G.G. Demonstration of tumor suppression by mannose 6-phosphate/insulin-like growth factor 2 receptor. Oncogene 23 58 (2004) 9359-9368
Rajaram S., Baylink D.J., and Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18 6 (1997) 801-831
Mohan S., and Baylink D.J. IGF-binding proteins are multifunctional and act via IGF-dependent and-independent mechanisms. J Endocrinol 175 1 (2002) 19-31
Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23 6 (2002) 824-854
Kelley K.M., Oh Y., Gargosky S.E., et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28 6 (1996) 619-637
Collett-Solberg P.F., and Cohen P. Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine 12 2 (2000) 121-136
Swisshelm K., Ryan K., Tsuchiya K., and Sager R. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci USA 92 10 (1995) 4472-4476
Akaogi K., Okabe Y., Funahashi K., et al. Cell adhesion activity of a 30-kDa major secreted protein from human bladder carcinoma cells. Biochem Biophys Res Commun 198 3 (1994) 1046-1053
Maroni P.D., Koul S., Meacham R.B., and Koul H.K. Mitogen activated protein kinase signal transduction pathways in the prostate. Cell Commun Signal 2 1 (2004) 5
Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2 July (7) (2002) 489-501
Zhao H., Dupont J., Yakar S., Karas M., and LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23 3 (2004) 786-794
Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22 14 (2004) 2954-2963
Cussenot O., and Cancel-Tassin G. Genetic susceptibility to prostate cancer. Med Sci (Paris) 20 5 (2004) 562-568
Rubin M.A., and De Marzo A.M. Molecular genetics of human prostate cancer. Mod Pathol 17 3 (2004) 380-388
Harrela M., Koistinen H., Kaprio J., et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 98 11 (1996) 2612-2615
Wolk A., Mantzoros C.S., Andersson S.O., et al. Insulin-like growth factor 1 and prostate ca, er risk: a population-based, case-control study. J Natl Cancer Inst 90 12 (1998) 911-915
Moyad M.A. Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. Urology 59 4 Suppl. 1 (2002) 41-50
Yip I., Heber D., and Aronson W. Nutrition and prostate cancer. Urol Clin North Am 26 2 (1999) 403-411
Tymchuk C.N., Barnard R.J., Ngo T.H., and Aronson W.J. Role of testosterone, estradiol, and insulin in diet- and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr Cancer 42 1 (2002) 112-116
Ngo T.H., Barnard R.J., Tymchuk C.N., Cohen P., and Aronson W.J. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro. Cancer Causes Control 13 10 (2002) 929-935
Tymchuk C.N., Tessler S.B., Aronson W.J., and Barnard R.J. Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 31 2 (1998) 127-131
Holmes M.D., Pollak M.N., Willett W.C., and Hankinson S.E. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 11 9 (2002) 852-861
Kaklamani V.G., Linos A., Kaklamani E., Markaki I., Koumantaki Y., and Mantzoros C.S. Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J Clin Oncol 17 10 (1999) 3291-3298
Kaklamani V.G., Linos A., Kaklamani E., Markaki I., and Mantzoros C. Age, sex, and smoking are predictors of circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3. J Clin Oncol 17 3 (1999) 813-817
Ngo T.H., Barnard R.J., Leung P.S., Cohen P., and Aronson W.J. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144 6 (2003) 2319-2324
Platz E.A., Pollak M.N., Rimm E.B., et al. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 8 12 (1999) 1107-1110
Kehinde E.O., Akanji A.O., Mojiminiyi O.A., Bashir A.A., Daar A.S., and Varghese R. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. Prostate Cancer Prostatic Dis 8 1 (2005) 84-90
Mantzoros C.S., Tzonou A., Signorello L.B., Stampfer M., Trichopoulos D., and Adami H.O. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76 9 (1997) 1115-1118
Kurek R., Tunn U.W., Eckart O., Aumuller G., Wong J., and Renneberg H. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 85 1 (2000) 125-129
Oliver S.E., Gunnell D., Donovan J., et al. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. Int J Cancer 108 6 (2004) 887-892
Khosravi J., Diamandi A., Mistry J., and Scorilas A. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer. J Clin Endocrinol Metab 86 February (2) (2001) 694-699
Li L., Yu H., Schumacher F., Casey G., and Witte J.S. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 14 8 (2003) 721-726
Chan J.M., Stampfer M.J., Ma J., et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94 14 (2002) 1099-1106
Chen C., Lewis S.K., Voigt L., Fitzpatrick A., Plymate S.R., and Weiss N.S. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 103 1 (2005) 76-84
Shariat S.F., Lamb D.J., Kattan M.W., et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20 3 (2002) 833-841
Woodson K., Tangrea J.A., Pollak M., et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 63 14 (2003) 3991-3994
Stattin P., Rinaldi S., Biessy C., Stenman U.H., Hallmans G., and Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol 22 15 (2004) 3104-3112
Cohen P. Serum insulin-like growth factor-I levels and prostate cancer risk-interpreting the evidence. J Natl Cancer Inst 90 12 (1998) 876-879
Shi R., Berkel H.J., and Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 85 7 (2001) 991-996
Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 5350 (1998) 563-566
Miyata Y., Sakai H., Kanda S., Igawa T., Hayashi T., and Kanetake H. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence. Urology 63 6 (2004) 1184-1190
Lopez J.B., Sahabudin R.M., and Chin L.P. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?. Int J Biol Markers 19 2 (2004) 164-167
Djavan B., Waldert M., Seitz C., and Marberger M. Insulin-like growth factors and prostate cancer. World J Urol 19 4 (2001) 225-233
Russell P.J., Bennett S., and Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 44 4 (1998) 705-723
Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 42 2 (2000) 150-160
Chung L.W. The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surv 23 (1995) 33-42
Cunha G.R., Donjacour A.A., Cooke P.S., et al. The endocrinology and developmental biology of the prostate. Endocr Rev 8 August (3) (1987) 338-362
Wong Y.C., Wang X.H., and Ling M.T. Prostate development and carcinogenesis. Int Rev Cytol 227 (2003) 65-130
Tennant M.K., Thrasher J.B., Twomey P.A., Drivdahl R.H., Birnbaum R.S., and Plymate S.R. Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81 10 (1996) 3774-3782
Plymate S.R., Tennant M., Birnbaum R.S., Thrasher J.B., Chatta G., and Ware J.L. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab 81 10 (1996) 3709-3716
Tennant M.K., Thrasher J.B., Twomey P.A., Birnbaum R.S., and Plymate S.R. Insulin-like growth factor-binding proteins (IGFBP)-4, -5, and -6 in the benign and malignant human prostate: IGFBP-5 messenger ribonucleic acid localization differs from IGFBP-5 protein localization. J Clin Endocrinol Metab 81 10 (1996) 3783-3792
Tennant M.K., Thrasher J.B., Twomey P.A., Birnbaum R.S., and Plymate S.R. Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab 81 1 (1996) 411-420
Stattin P., Bylund A., Rinaldi S., et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92 23 (2000) 1910-1917
Horoszewicz J.S., Leong S.S., Kawinski E., et al. LNCaP model of human prostatic carcinoma. Cancer Res 43 April (4) (1983) 1809-1818
Nickerson T., Chang F., Lorimer D., Smeekens S.P., Sawyers C.L., and Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen-independence is associated with increased expression of insulin-like growth factor I (IGF-and IGF-I receptor (IGF-IR)). Cancer Res 61 August (16) (2001) 6276-6280
Vlietstra R.J., van Alewijk D.C., Hermans K.G., van Steenbrugge G.J., and Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58 July (13) (1998) 2720-2723
Werner H., and Roberts Jr. C.T. The IGFI receptor gene: a molecular target for disrupted transcription factors. Genes Chromosomes Cancer 36 2 (2003) 113-120
Krueckl S.L., Sikes R.A., Edlund N.M., et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 64 23 (2004) 8620-8629
Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F., and Macaulay V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62 10 (2002) 2942-2950
Plymate S.R., Bae V.L., Maddison L., Quinn L.S., and Ware J.L. Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 138 4 (1997) 1728-1735
Kaplan P.J., Mohan S., Cohen P., Foster B.A., and Greenberg N.M. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59 9 (1999) 2203-2209
Buckbinder L., Talbott R., Velasco-Miguel S., et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377 6550 (1995) 646-649
Rajah R., Valentinis B., and Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272 18 (1997) 12181-12188
Gucev Z.S., Oh Y., Kelley K.M., and Rosenfeld R.G. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 56 7 (1996) 1545-1550
Colston K.W., Perks C.M., Xie S.P., and Holly J.M. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by Vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20 1 (1998) 157-162
Rozen F., Zhang J., and Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 13 4 (1998) 865-869
Rajah R., Lee K.W., and Cohen P. Insulin-like growth factor binding protein-3 mediates tumor necrosisfactor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth Differ 13 4 (2002) 163-171
Rajah R., Khare A., Lee P.D., and Cohen P. Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol 163 3 (1999) 487-494
Hong J., Zhang G., Dong F., and Rechler M.M. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 277 12 (2002) 10489-10497
Oh Y., Muller H.L., Pham H., and Rosenfeld R.G. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268 35 (1993) 26045-26048
Oh Y., Muller H.L., Lamson G., and Rosenfeld R.G. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268 20 (1993) 14964-14971
Leal S.M., Huang S.S., and Huang J.S. Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. J Biol Chem 274 10 (1999) 6711-6717
Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22 42 (2003) 6589-6597
Kanety H., Madjar Y., Dagan Y., et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77 1 (1993) 229-233
Moore M.G., Wetterau L.A., Francis M.J., Peehl D.M., and Cohen P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 105 1 (2003) 14-19
Inman B.A., Harel F., Audet J.F., et al. Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. Eur Urol 47 5 (2005) 695-702
Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4 7 (2004) 505-518
Levitt R., Georgescu M., and Pollak M. PTEN-induced apoptosis in U251 glioma cells is associated with decreased expression of insulin-like growth factor binding protein-2. AACR annual meeting (2005) [abstract 4576]
Koistinen H., Paju A., Koistinen R., et al. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50 2 (2002) 112-118
Hwa V., Tomasini-Sprenger C., Bermejo A.L., Rosenfeld R.G., and Plymate S.R. Characterization of insulin-like growth factor-binding protein-related protein-1 in prostate cells. J Clin Endocrinol Metab 83 12 (1998) 4355-4362
Mutaguchi K., Yasumoto H., Mita K., et al. Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 63 22 (2003) 7717-7723
Lopez-Bermejo A., Buckway C.K., Devi G.R., et al. Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium. Endocrinology 141 11 (2000) 4072-4080
McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., and Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59 17 (1999) 4291-4296
McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52 24 (1992) 6940-6944
Pfeil K., Eder I.E., Putz T., et al. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58 3 (2004) 259-268
Greenberg N.M., DeMayo F., Finegold M.J., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92 April (8) (1995) 3439-3443
Foster B.A., Kaplan P.J., and Greenberg N.M. Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev 17 4 (1998-1999) 317-324
Wetterau L.A., Francis M.J., Ma L., and Cohen P. Insulin-like growth factor I stimulates telomerase activity in prostate cancer cells. J Clin Endocrinol Metab 88 7 (2003) 3354-3359
Kahan Z., Arencibia J.M., Csernus V.J., et al. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84 2 (1999) 582-589
Schally A.V., and Varga J.L. Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol Metab 10 10 (1999) 383-391
Plonowski A., Schally A.V., Varga J.L., et al. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 44 2 (2000) 172-180
Letsch M., Schally A.V., Busto R., Bajo A.M., and Varga J.L. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 100 3 (2003) 1250-1255
Ruan W., Powell-Braxton L., Kopchick J.J., and Kleinberg D.L. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140 5 (1999) 1984-1989
Marelli M.M., Moretti R.M., Dondi D., Motta M., and Limonta P. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140 1 (1999) 329-334
Moretti R.M., Marelli M.M., Dondi D., et al. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81 11 (1996) 3930-3937
Gori F., Hofbauer L.C., Conover C.A., and Khosla S. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 140 December (12) (1999) 5579-5586
Goel H.L., Fornaro M., Moro L., et al. Selective modulation of type 1 insulin-like growth factor receptor signalling and functions by beta1 integrins. J Cell Biol 166 3 (2004) 407-418
Damsky C.H., and Ilic D. Integrin signaling: it's where the action is. Curr Opin Cell Biol 14 5 (2002) 594-602
Fornaro M., Manes T., and Languino L.R. Integrins and prostate cancer metastases. Cancer Metastasis Rev 20 3-4 (2001) 321-331
Mauro L., and Surmacz E. IGF-I receptor, cell-cell adhesion, tumour development and progression. J Mol Histol 35 3 (2004) 247-253
Maile L.A., Badley-Clarke J., and Clemmons D.R. Structural analysis of the role of the beta 3 subunit of the alpha V beta 3 integrin in IGF-I signaling. J Cell Sci 114 Pt 7 (2001) 1417-1425
Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8 2 (1989) 98-101
Yonou H., Yokose T., Kamijo T., et al. Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 61 5 (2001) 2177-2182
Logothetis C.J., and Lin S.H. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5 1 (2005) 21-28
Ritchie C.K., Andrews L.R., Thomas K.G., Tindall D.J., and Fitzpatrick L.A. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. Endocrinology 138 3 (1997) 1145-1150
Rubin J., Ackert-Bicknell C.L., Zhu L., et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 87 September (9) (2002) 4273-4279
Fizazi K., Yang J., Peleg S., et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9 7 (2003) 2587-2597
Rubin J., Chung L.W., Fan X., et al. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. Prostate 58 1 (2004) 41-49
Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 2 (1997) 309-319
Boyce B.F., Yoneda T., and Guise T.A. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 6 3 (1999) 333-347
Clarke N.W., McClure J., and George N.J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 68 1 (1991) 74-80
Garnero P., Buchs N., Zekri J., Rizzoli R., Coleman R.E., and Delmas P.D. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82 4 (2000) 858-864
Bogdanos J., Karamanolakis D., Tenta R., et al. Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer 10 2 (2003) 279-289
Goya M., Miyamoto S., Nagai K., et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 64 17 (2004) 6252-6258
Miyake H., Nelson C., Rennie P.S., and Gleave M.E. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway. Endocrinology 141 6 (2000) 2257-2265
Gurumurthy S., Vasudevan K.M., and Rangnekar V.M. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 20 3-4 (2001) 225-243
Grossmann M.E., Huang H., and Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93 22 (2001) 1687-1697
Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 1 (2001) 34-45
Orio Jr. F., Terouanne B., Georget V., et al. Potential action of IGF-1 and EGF on androgen receptor nuclear transfer and transactivation in normal and cancer human prostate cell lines. Mol Cell Endocrinol 198 1-2 (2002) 105-114
Pandini G., Mineo R., Frasca F., et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res 65 5 (2005) 1849-1857
Nelson J.B., Chan-Tack K., Hedican S.P., et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 56 4 (1996) 663-668
Renehan A.G., Zwahlen M., Minder C., O'Dwyer S.T., Shalet S.M., and Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 9418 (2004) 1346-1353
Sehgal I., Powers S., Huntley B., Powis G., Pittelkow M., and Maihle N.J. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc Natl Acad Sci USA 91 11 (1994) 4673-4677
Markwalder R., and Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59 5 (1999) 1152-1159
Rao G.N., Delafontaine P., and Runge M.S. Thrombin stimulates phosphorylation of insulin-like growth factor-1 receptor, insulin receptor substrate-1, and phospholipase C-gamma 1 in rat aortic smooth muscle cells. J Biol Chem 270 46 (1995) 27871-27875
Du J., Sperling L.S., Marrero M.B., Phillips L., and Delafontaine P. G-protein and tyrosine kinase receptor cross-talk in rat aortic smooth muscle cells: thrombin- and angiotensin II-induced tyrosine phosphorylation of insulin receptor substrate-1 and insulin-like growth factor 1 receptor. Biochem Biophys Res Commun 218 3 (1996) 934-939
Daub H., Weiss F.U., Wallasch C., and Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379 6565 (1996) 557-560
Linseman D.A., Benjamin C.W., and Jones D.A. Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem 270 21 (1995) 12563-12568
Culig Z., Hobisch A., Hittmair A., et al. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate 32 2 (1997) 106-114
Sumitomo M., Milowsky M.I., Shen R., et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 61 8 (2001) 3294-3298
Sumitomo M., Shen R., Walburg M., et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Invest 106 11 (2000) 1399-1407
Dai J., Shen R., Sumitomo M., et al. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. Clin Cancer Res 7 5 (2001) 1370-1377
Nickerson T., Pollak M., and Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5. Endocrinology 139 2 (1998) 807-810
Thomas L.N., Cohen P., Douglas R.C., Lazier C., and Rittmaster R.S. Insulin-like growth factor binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride-treated rats. Prostate 35 4 (1998) 273-278
Nickerson T., and Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology 54 6 (1999) 1120-1125
Huynh H., Pollak M., and Zhang J.C. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by Vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol 13 1 (1998) 137-143
Huynh H., Seyam R.M., and Brock G.B. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 58 2 (1998) 215-218
Nickerson T., Miyake H., Gleave M.E., and Pollak M. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. Cancer Res 59 14 (1999) 3392-3395
Miyake H., Pollak M., and Gleave M.E. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 60 11 (2000) 3058-3064
Kiyama S., Morrison K., Zellweger T., et al. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 63 13 (2003) 3575-3584
Schulz P., Link T.A., Chaudhuri L., and Fittler F. Role of the mitochondrial bc1-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells. Cancer Res 50 16 (1990) 5008-5012
Koike H., Ito K., Takezawa Y., Oyama T., Yamanaka H., and Suzuki K. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer. Br J Cancer 92 8 (2005) 1538-1544
McCarty M.F. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integr Cancer Ther 3 4 (2004) 349-380
van der Poel H.G. Smart drugs in prostate cancer. Eur Urol 45 1 (2004) 1-17
Jerome L., Shiry L., and Leyland-Jones B. Anti-insulin-like growth factor strategies in breast cancer. Semin Oncol 31 1 Suppl. 3 (2004) 54-63
Pollak M.N., and Schally A.V. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 217 2 (1998) 143-152
Ibrahim Y.H., and Yee D. Insulin-like growth factor-I and breast cancer therapy. Clin Cancer Res 11 2 Pt 2 (2005) 944s-950s
Siegel R.A., Tolcsvai L., and Rudin M. Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995). Cancer Res 48 16 (1988) 4651-4655
Szende B., and Keri G. TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anticancer Drugs 14 8 (2003) 585-588
Liebow C., Reilly C., Serrano M., and Schally A.V. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 86 6 (1989) 2003-2007
Szereday Z., Schally A.V., Szepeshazi K., et al. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238. Int J Oncol 22 5 (2003) 1141-1146
Koutsilieris M., Mitsiades C., Dimopoulos T., Ioannidis A., Ntounis A., and Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 86 12 (2001) 5729-5736
Jansen B., and Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol 3 November (11) (2002) 672-683
Chi K.N., and Gleave M.E. Antisense approaches in prostate cancer. Expert Opin Biol Ther 4 June (6) (2004) 927-936
Ho P.T., and Parkinson D.R. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol 24 April (2) (1997) 187-202
Burfeind P., Chernicky C.L., Rininsland F., Ilan J., and Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93 14 (1996) 7263-7268
Resnicoff M., Abraham D., Yutanawiboonchai W., et al. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55 11 (1999) 2463-2469
Resnicoff M., Tjuvajev J., Rotman H.L., et al. Regression of C6 rat brain tumors by cells expressing an antisense insulin-like growth factor I receptor RNA. J Exp Ther Oncol 1 6 (1996) 385-389
Neuenschwander S., Roberts Jr. C.T., and LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 136 10 (1995) 4298-4303
Chernicky C.L., Yi L., Tan H., Gan S.U., and Ilan J. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 7 3 (2000) 384-395
Hellawell G.O., Ferguson D.J., Brewster S.F., and Macaulay V.M. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor. BJU Int 91 3 (2003) 271-277
Andrews D.W., Resnicoff M., Flanders A.E., et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19 8 (2001) 2189-2200
Bohula E.A., Salisbury A.J., Sohail M., et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem 278 May (18) (2003) 15991-15997
Rye P.D., and Stigbrand T. Interfering with cancer: a brief outline of advances in RNA interference in oncology. Tumour Biol 25 September-December (5-6) (2004) 329-336
Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 February (6669) (1998) 806-811
Rochester M.A., Riedemann J., Hellawell G.O., Brewster S.F., and Macaulay V.M. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther 12 1 (2005) 90-100
Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 3 (2004) 221-230
Seely B.L., Samimi G., and Webster N.J. Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer 2 1 (2002) 15
van der Poel H.G., Hanrahan C., Zhong H., and Simons J.W. Rapamycin induces Smad activity in prostate cancer cell lines. Urol Res 30 6 (2003) 380-386
Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., and Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 62 21 (2002) 6141-6145
Mousses S., Wagner U., Chen Y., et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 20 46 (2001) 6718-6723
Neshat M.S., Mellinghoff I.K., Tran C., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98 18 (2001) 10314-10319
Stern M., and Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54 1 (2005) 11-29
Hailey J., Maxwell E., Koukouras K., Bishop W.R., Pachter J.A., and Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 1 14 (2002) 1349-1353
Gansler T., Furlanetto R., Gramling T.S., et al. Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice. Am J Pathol 135 6 (1989) 961-966
Scotlandi K., Benini S., Nanni P., et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 58 18 (1998) 4127-4131
Kalebic T., Tsokos M., and Helman L.J. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 54 21 (1994) 5531-5534
Sachdev D., Li S.L., Hartell J.S., Fujita-Yamaguchi Y., Miller J.S., and Yee D. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 63 3 (2003) 627-635
Maloney E.K., McLaughlin J.L., Dagdigian N.E., et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63 16 (2003) 5073-5083
Park J.W., and Smolen J. Monoclonal antibody therapy. Adv Protein Chem 56 (2001) 369-421
Hofmann F., and Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10 August (15) (2005) 1041-1047
Goetsch L., Gonzalez A., Leger O., et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113 2 (2005) 316-328
Burtrum D., Zhu Z., Lu D., et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63 24 (2003) 8912-8921
Wu J.D., Odman A., Higgins L.M., et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 11 8 (2005) 3065-3074
Plymate S., Wu J., Odman A., Vessella R., and Ludwig D. Inhibition of IGF-IR signalling with the human monoclonal antibody A12 enhances the therapeutic effect of docetaxelin prostate cancer. AACR annual meeting (2005) [abstract 5037]
Wu K., Zhou L., Zhang K., Burtrum D., Ludwig D., and Moore M. A humanized insulin-like growth factor I receptor antibody inhibits multiple myeloma cell growth in vivo through anti-angiogenesis. AACR annual meeting (2005) [abstract 5036]
Cohen B.D., Baker D.A., Soderstrom C., et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11 5 (2005) 2063-2073
Wang Y., Hailey J., Williams D., et al. Inhibition of IGF-IR signaling and tumor cell proliferation by a fully human neutralizing anti-IGF-IR antibody. AACR annual meeting (2005) [abstract 5038]
Wang X., Lipari P., Liu L., et al. Efficacy of human anti-IGF-IR antibody in tumor xenograft models as a single agent and in combination with anti-cancer drugs. AACR annual meeting (2005) [abstract 5039]
Garcia-Echeverria C., Pearson M.A., Marti A., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 3 (2004) 231-239
Warshamana-Greene G.S., Litz J., Buchdunger E., Garcia-Echeverria C., Hofmann F., and Krystal G.W. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 11 4 (2005) 1563-1571
Scotlandi K., Manara M.C., Nicoletti G., et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 65 9 (2005) 3868-3876
Grosios K., Hofmann F., Bruggen J., et al. Characterization of a novel small molecular weight IGF-IR inhibitor. AACR annual meeting (2005) [abstract 5977]
Carboni J., Wittman M., Attar R., et al. BMS-536924, a potent small molecule inhibitor of the IGF-I receptor in vitro and in vivo. AACR annual meeting (2005) [abstract 5976]
Stromberg T., Ekman S., Girnita L., et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood September (2005) (ahead of print)
Menu E., Jernberg Wiklund H., Stromberg T., et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood July (2005) (ahead of print)
Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O., and Axelson M. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 64 January (1) (2004) 236-242
Putz T., Culig Z., Eder I.E., et al. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59 1 (1999) 227-233
Connolly J.M., and Rose D.P. Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24 4 (1994) 167-175
Lu D., Zhang H., Ludwig D., et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279 4 (2004) 2856-2865
Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 1 (2002) 200-207
Jones H.E., Goddard L., Gee J.M., et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11 4 (2004) 793-814
Chatterjee S., Park E.S., and Soloff M.S. Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int J Urol 11 10 (2004) 876-884
Jerome L., Shiry L., and Leyland-Jones B. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 10 4 (2003) 561-578
Fowler C.A., Perks C.M., Newcomb P.V., Savage P.B., Farndon J.R., and Holly J.M. Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int J Cancer 88 3 (2000) 448-453
Lee D.Y., Yi H.K., Hwang P.H., and Oh Y. Enhanced expression of insulin-like growth factor binding protein-3 sensitizes the growth inhibitory effect of anticancer drugs in gastric cancer cells. Biochem Biophys Res Commun 294 2 (2002) 480-486
Lee H.Y., Chun K.H., Liu B., et al. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 62 12 (2002) 3530-3537
Lu Y., Zi X., Zhao Y., Mascarenhas D., and Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93 24 (2001) 1852-1857
Jerome L, Yu Q, Belanger S, et al. Recombinant human insulin-like growth factor binding-protein-3 (rhIGFBP-3) as a potential therapeutic agent for the treatment of Herceptin-resistant breast cancer. In: 26th Annual San Antonio Breast Cancer Symposium. 2003.
Blouin M, Shiry L, Lehnert S, Zhao Y, Pollak M. IGFBP-3 enhances sensitivity to radiation therapy in vitro and inhibits tumor formation in vivo in a model of human breast cancer. In: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2004.
Damon S.E., Maddison L., Ware J.L., and Plymate S.R. Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. Endocrinology 139 8 (1998) 3456-3464
Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., and Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64 August (15) (2004) 5355-5362
Garber K. IGF-I: old growth factor shines as new drug target. J Natl Cancer Inst 97 11 (2005)
Reiss K., Wang J.Y., Romano G., Tu X., Peruzzi F., and Baserga R. Mechanisms of regulation of cell adhesion and motility by insulin receptor substrate-1 in prostate cancer cells. Oncogene 20 January (4) (2001) 490-500